Comparative Pharmacology
Head-to-head clinical analysis: TRIPROLIDINE HYDROCHLORIDE versus XYZAL ALLERGY 24HR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: TRIPROLIDINE HYDROCHLORIDE versus XYZAL ALLERGY 24HR.
TRIPROLIDINE HYDROCHLORIDE vs XYZAL ALLERGY 24HR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Competitive antagonist of histamine H1 receptors; inhibits histamine-mediated vasodilation, increased capillary permeability, and bronchoconstriction in allergic reactions.
Levocetirizine is the active R-enantiomer of cetirizine, a second-generation antihistamine. It selectively inhibits peripheral H1 receptors, reducing histamine-mediated allergic responses such as itching, sneezing, and rhinorrhea.
2.5 mg orally every 4-6 hours as needed; maximum 10 mg per 24 hours.
5 mg (1 tablet) orally once daily, preferably in the evening.
None Documented
None Documented
Terminal elimination half-life approximately 3–4 hours in healthy adults; prolonged in renal impairment (up to 12 hours).
Terminal elimination half-life is approximately 8-9 hours in healthy adults. In patients with renal impairment (CrCl <30 mL/min), half-life may be prolonged to up to 21 hours.
Renal (primarily as metabolites; ~70% recovered in urine within 24 hours, <5% unchanged). Fecal elimination is minor.
Primarily renal excretion; approximately 85% of the dose is excreted unchanged in urine, with the remainder as metabolites (mainly the conjugate) in feces via biliary elimination (~10-13%).
Category A/B
Category C
Antihistamine
Antihistamine